GlassScriptPhysician profile
Elizabeth R Choby
NPI 1578955118
$15,827.53
in general payments reported to CMS, 2019-2025
67 companies · $4,767 in 2025
The $4,767 reported for 2025 was more than what 98% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $870 · 2022: $2,824 · 2023: $3,787 · 2024: $3,579 · 2025: $4,767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,913.49 |
| Education | $219.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $1,342.47 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Celgene Corporation | $1,270.00 | 2021-2025 | Reblozyl, Pomalyst, Opdualag |
| Janssen Biotech, INC. | $1,250.05 | 2021-2025 | Darzalex, Erleada, Rybrevant |
| Novartis Pharmaceuticals Corporation | $1,242.77 | 2021-2025 | |
| Pfizer INC. | $1,059.06 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $964.80 | 2021-2025 | Tagrisso, Lynparza, Enhertu |
| Genzyme Corporation | $800.34 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $755.04 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Seagen INC. | $415.11 | 2021-2023 | Tukysa, Adcetris, Padcev |
| Daiichi Sankyo INC. | $391.65 | 2022-2025 | Enhertu, Injectafer, Datroway |
| Abbvie INC. | $382.76 | 2021-2025 | |
| Glaxosmithkline, LLC. | $355.69 | 2022-2025 | Zejula, Jemperli, Shingrix |
| Sobi, INC | $352.64 | 2022-2025 | |
| Astellas Pharma US INC | $346.00 | 2021-2025 | Xtandi, Padcev |
| Array Biopharma INC | $289.06 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $275.74 | 2021-2025 | Opdualag, Opdivo |
| Amgen INC. | $265.56 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $239.65 | 2021-2025 | |
| Puma Biotechnology, INC. | $211.55 | 2021-2025 | |
| Lilly USA, LLC | $210.71 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Pharmacyclics LLC, An Abbvie Company | $203.52 | 2021-2023 | Imbruvica, Epkinly |
| Gilead Sciences, INC. | $202.72 | 2022-2025 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $186.24 | 2022-2025 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $176.36 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $162.65 | 2021-2025 | Onivyde, Somatuline Depot, Tazverik |
| Karyopharm Therapeutics INC. | $160.38 | 2021-2025 | Xpovio |
| Stemline Therapeutics INC. | $139.62 | 2024-2025 | Orserdu |
| Servier Pharmaceuticals LLC | $139.20 | 2022-2025 | |
| Beigene USA, INC. | $124.71 | 2022-2025 | Brukinsa, Tevimbra |
| Pharmacosmos Therapeutics INC. | $123.70 | 2023-2025 | Monoferric, Cosela |
| Takeda Pharmaceuticals U.S.A., INC. | $117.58 | 2023-2025 | Iclusig, Fruzaqla, Ninlaro |
| Kyowa Kirin, INC. | $113.26 | 2023-2025 | Poteligeo |
| Tersera Therapeutics LLC | $98.88 | 2023-2025 | Zoladex |
| Eisai INC. | $97.54 | 2022-2025 | |
| Myriad Genetic Laboratories, INC. | $92.27 | 2021-2023 | Precisetumor, Mychoice Cdx |
| Geron Corporation | $86.76 | 2025 | Rytelo |
| Emd Serono, INC. | $75.93 | 2023-2025 | Bavencio |
| Taiho Oncology, INC. | $74.05 | 2021-2024 | |
| Pharmaessentia USA Corporation | $73.64 | 2024-2025 | Besremi |
| Genentech USA, INC. | $68.11 | 2025 | Itovebi |
| Recordati_rare_diseases_inc. | $67.97 | 2024-2025 | Sylvant, Enjaymo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.14 | 2024-2025 | |
| Mirati Therapeutics, INC. | $64.77 | 2023-2024 | Krazati |
| Dendreon Pharmaceuticals LLC | $58.05 | 2025 | Provenge |
| Novocure INC. | $52.89 | 2024-2025 | Optune Lua (Novottf-200t), Optune |
| Legend Biotech USA INC. | $47.92 | 2024-2025 | Carvykti |
| Alexion Pharmaceuticals, INC. | $46.79 | 2023-2025 | Ultomiris |
| G1 Therapeutics, INC. | $41.82 | 2022-2023 | Cosela |
| Beone Medicines USA, INC. | $40.08 | 2025 | Brukinsa |
| Exelixis INC. | $34.83 | 2025 | Cabometyx |
| Tolmar, INC. | $31.23 | 2024-2025 | Rubraca, Eligard |
| Aveo Pharmaceuticals, INC. | $29.72 | 2025 | |
| Dova Pharmaceuticals | $29.31 | 2021 | |
| Alnylam Pharmaceuticals INC. | $26.52 | 2023 | Givlaari |
| Iovance Biotherapeutics, INC. | $25.83 | 2025 | Amtagvi |
| Adc Therapeutics America, INC. | $24.96 | 2025 | |
| Lundbeck LLC | $24.23 | 2024 | Vyepti |
| Agios Pharmaceuticals, INC. | $22.69 | 2025 | Pyrukynd |
| Biocon Biologics INC | $21.41 | 2024 | Ogivri |
| Genmab U.S., INC. | $20.33 | 2025 | Epkinly |
| Eusa Pharma (US) LLC | $17.29 | 2021 | |
| Heron Therapeutics, INC. | $16.98 | 2022 | |
| Macrogenics, INC. | $16.89 | 2023 | |
| Cti Biopharma Corp. | $16.29 | 2022 | |
| Pharmaand Gmbh | $16.06 | 2025 | Rubraca |
| Adaptive Biotechnologies Corporation | $14.12 | 2025 | Clonoseq |
| Sun Pharmaceutical Industries INC. | $13.64 | 2025 |
Drugs and devices associated with these payments
Keytruda $692Jakafi $626Reblozyl $546Sarclisa $442Tukysa $437Kisqali $416Pluvicto $402Enhertu $382Lynparza $345Darzalex $341Padcev $336Ibrance $314Jemperli $286Zejula $286Braftovi $272Erleada $257Xtandi $251Mektovi $251Rybrevant $251Tecvayli $244Adcetris $242Tagrisso $240Pomalyst $231Elrexfio $213Monjuvi $206Lorbrena $203Pemazyre $199Vonjo $185Opdualag $182Libtayo $173Piqray $161Imbruvica $158Jaypirca $146Nubeqa $145Xofigo $145Orserdu $140Verzenio $126Venclexta $121Xpovio $119Zepzelca $115Lutathera $114Poteligeo $113Opdivo $112Akeega $111Talvey $108Onivyde $105Balversa $103Welireg $102Elahere $100Zoladex $98.88Jevtana $95.88Talzenna $93.90Trodelvy $89.52Bosulif $87.42Rytelo $86.76Monoferric $85.37Brukinsa $75.55Besremi $73.64Lenvima $72.42Oxbryta $69.12Itovebi $68.11Orgovyx $65.25Doptelet $65.10Krazati $64.77Epkinly $62.44Cosela $58.74Tivdak $58.22Provenge $58.05Enjaymo $51.13Xalkori $51.02Tibsovo $50.32Bavencio $49.16Ultomiris $46.79Somatuline Depot $46.40Injectafer $46.11Cablivi $45.86Sylvant $41.33Tazverik $40.02Bevespi Aerosphere $39.05Nerlynx $35.31Lonsurf $35.09Inqovi $35.09Cabometyx $34.83Lupron Depot $34.16Optune Lua (Novottf-200t) $33.79Eligard $31.23Stivarga $30.93Vitrakvi $30.93Rubraca $30.75Fotivda $29.72Iclusig $28.87Inlyta $28.65Elitek $28.65Datroway $26.91Givlaari $26.52Fruzaqla $26.13Ninlaro $26.04Amtagvi $25.83Zynlonta $24.96Vyepti $24.23
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Choby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.